OTCMKTS:EKTAY Elekta AB (publ) (EKTAY) Stock Price, News & Analysis → If you own NVIDIA, read this now (From Porter & Company) (Ad) Free EKTAY Stock Alerts $8.03 +0.02 (+0.25%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$7.98▼$8.0350-Day Range$6.70▼$8.0352-Week Range$6.52▼$8.62Volume3,435 shsAverage Volume8,477 shsMarket Capitalization$3.08 billionP/E Ratio22.29Dividend Yield1.99%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendEarningsFinancialsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartDividendEarningsFinancialsHeadlinesShort Interest Get Elekta AB (publ) alerts: Email Address Ad Porter & CompanyIf you own NVIDIA, read this now Forget investing in Nvidia or Microsoft. Because there is only ONE AI company that matters. It’s a U.S-based firm you’ve never heard of before – one that isn’t even involved in the artificial intelligence conversation. But here’s what nobody else has spotted: without this company’s new technology, the entire AI market could collapse. I call it “The AI Keystone.” About Elekta AB (publ) Stock (OTCMKTS:EKTAY)Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.Read More EKTAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EKTAY Stock News HeadlinesMarch 1, 2024 | gurufocus.comQ3 2024 Elekta AB (publ) Earnings Call TranscriptFebruary 23, 2024 | msn.comElekta AB (publ) goes ex dividend MondayFebruary 20, 2024 | finance.yahoo.comIs Elekta (EKTAY) Stock Undervalued Right Now?December 17, 2023 | msn.comElekta AB - ADR (EKTAY) Price Target Increased by 5.21% to 8.43December 7, 2023 | finance.yahoo.comIs Elekta (EKTAY) a Great Value Stock Right Now?November 27, 2023 | msn.comElekta AB - ADR (EKTAY) Price Target Increased by 6.97% to 8.01November 9, 2023 | morningstar.comElekta AB ADR EKTAYNovember 8, 2023 | msn.comElekta gets $40m radiation tech contract from India’s KIMSOctober 23, 2023 | stockhouse.comiCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to ElektaAugust 26, 2023 | seekingalpha.comElekta AB (publ) 2024 Q1 - Results - Earnings Call PresentationAugust 26, 2023 | seekingalpha.comElekta AB (publ) (EKTAF) Q1 2024 Earnings Call TranscriptJuly 19, 2023 | wsj.comElekta AB Series BApril 30, 2023 | seekingalpha.comEpiroc AB (publ) 2023 Q1 - Results - Earnings Call PresentationNovember 24, 2022 | finance.yahoo.comEuropean shares struggle for direction as traders weigh rate outlookNovember 5, 2022 | finance.yahoo.comElekta AB (publ) (EKTAY)October 13, 2022 | finance.yahoo.comElekta AB (publ) (EKTA-B.ST)October 9, 2022 | fool.comELEKTA B SHS ADR (OTC: EKTAY)October 2, 2022 | reuters.comElekta AB (publ)August 27, 2022 | seekingalpha.comElekta AB (publ) 2023 Q1 - Results - Earnings Call PresentationAugust 25, 2022 | seekingalpha.comElekta AB (publ) (EKTAF) Q1 2023 Earnings Call TranscriptAugust 25, 2022 | finance.yahoo.comEdited Transcript of EKTAb.ST earnings conference call or presentation 25-Aug-22 8:00am GMTMay 15, 2022 | seekingalpha.comElekta (EKTAY) Presents at ESTRO 2022February 24, 2022 | finance.yahoo.comElekta: Interim report, May-January 2021/22January 7, 2022 | seekingalpha.comNew finance chief at ElektaJanuary 7, 2022 | finance.yahoo.comElekta to appoint Tobias Hägglöv as Chief Financial OfficerSee More Headlines Receive EKTAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elekta AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 3/18 Dividend2/26/2024Last Earnings2/29/2024Dividend Payable3/18/2024Today5/25/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolOTCMKTS:EKTAY CUSIPN/A CIK1451160 Webwww.elekta.com Phone(685) 872-5400Fax46-8-587-255-00Employees4,540Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.36 Trailing P/E Ratio22.29 Forward P/E Ratio19.57 P/E GrowthN/ANet Income$90.25 million Net Margins7.88% Pretax MarginN/A Return on Equity15.16% Return on Assets5.01% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.61 billion Price / Sales1.91 Cash Flow$0.56 per share Price / Cash Flow14.27 Book Value$2.43 per share Price / Book3.30Miscellaneous Outstanding Shares383,570,000Free Float225,231,000Market Cap$3.08 billion OptionableNot Optionable Beta1.16 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Laurent Leksell (Age 72)Founder & Chairman Comp: $1.64MMr. Gustaf Salford (Age 47)President & CEO Comp: $14.62MMr. Tobias Hagglov (Age 46)Chief Financial Officer Mr. Peter Nyquist (Age 59)Head of Investor Relations Mr. Jonas Bolander (Age 58)Executive VP of Group Functions, Secretary & General Counsel Mr. Mattias ThorssonVP and Head of Corporate Communications & Public AffairsMs. Anna Conneryd Lundgren (Age 39)Executive VP & Chief People Officer Mr. John Lapré (Age 60)President of Brachy & Neuro Solutions Mr. Maurits Wolleswinkel (Age 53)President of Linac & Software Solutions Mr. Habib Nehme (Age 60)Chief Commercial Officer More ExecutivesKey CompetitorsGuardant HealthNASDAQ:GHFortreaNASDAQ:FTRERadNetNASDAQ:RDNTVeracyteNASDAQ:VCYTViridian TherapeuticsNASDAQ:VRDNView All Competitors EKTAY Stock Analysis - Frequently Asked Questions Should I buy or sell Elekta AB (publ) stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elekta AB (publ) in the last year. There are currently 2 sell ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" EKTAY shares. View EKTAY analyst ratings or view top-rated stocks. How have EKTAY shares performed in 2024? Elekta AB (publ)'s stock was trading at $8.1495 at the start of the year. Since then, EKTAY stock has decreased by 1.5% and is now trading at $8.0250. View the best growth stocks for 2024 here. Are investors shorting Elekta AB (publ)? Elekta AB (publ) saw a drop in short interest in April. As of April 30th, there was short interest totaling 100 shares, a drop of 98.9% from the April 15th total of 9,400 shares. Based on an average daily trading volume, of 38,600 shares, the short-interest ratio is currently 0.0 days. View Elekta AB (publ)'s Short Interest. How were Elekta AB (publ)'s earnings last quarter? Elekta AB (publ) (OTCMKTS:EKTAY) announced its quarterly earnings results on Thursday, February, 29th. The company reported $0.08 earnings per share for the quarter. The firm earned $426.51 million during the quarter. Elekta AB (publ) had a trailing twelve-month return on equity of 15.16% and a net margin of 7.88%. How often does Elekta AB (publ) pay dividends? What is the dividend yield for Elekta AB (publ)? Elekta AB (publ) announced a dividend on Tuesday, January 30th. Stockholders of record on Tuesday, February 27th will be paid a dividend of $0.1146 per share on Monday, March 18th. The ex-dividend date is Monday, February 26th. Read our dividend analysis for EKTAY. Is Elekta AB (publ) a good dividend stock? Elekta AB (publ) (OTCMKTS:EKTAY) pays an annual dividend of $0.16 per share and currently has a dividend yield of 1.98%. The dividend payout ratio is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, EKTAY will have a dividend payout ratio of 34.04% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for EKTAY. How do I buy shares of Elekta AB (publ)? Shares of EKTAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:EKTAY) was last updated on 5/25/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersUrgent Nvidia WarningAltimetryBiden FINISHED On June 13th?Paradigm PressThis could mean the end of the U.S dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceJust $9 for a Year of Winning Market InsightsBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elekta AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.